Replies to post #122140 on Biotech Values

[BTH]

Yes, its a legitimate financing without warrants...from good firms.

Poor Rodman...I'm sure the were hoping they were going to be giving their clients an opportunity for a ton of warrants at a fifty percent discount to market.

[mcbio]

Everyone knew the company needed cash, and they got cash at a discount of only 2% to Tuesday’s closing price with no warrants. That’s a positive development for a clinical-stage biotech company.

Thanks DD. Makes sense.

Separately, which side of the fence are you on vis-a-vis ACHN: my optimistic take on ACHN that there will be room for an HCV PI, like 1625 or 2684, in the future of HCV treatment, and in particular enough room to have a meaningful impact on ACHN's current market cap or oc631's bearish take on ACHN in that the VRUS nukes will solely dominate the future of HCV treatment, leaving little to no room for any HCV drugs from other classes?

[biomaven0]

Everyone knew the company needed cash, and they got cash at a discount of only 2% to Tuesday’s closing price with no warrants.

There are hedge funds that short biotechs that need cash, hoping to cover at a discount in the offering and maybe clip some warrants in the process. So sometimes when their hopes are dashed you see short covering after the offering.

Strength after offerings has historically been a very good sign of a strong biotech market.

Peter